13D Filing: Ventech Capital II and Eyegate Pharmaceuticals Inc (EYEG)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of
1934

(Amendment No. 1)

EyeGate Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

30233M 107

(CUSIP Number)

Stephen Brook, Esq.
Burns & Levinson LLP

125 Summer Street

Boston, MA 02110

(617) 345-3000

(Name, Address and Telephone Number of
Person Authorized to Receive Notices and Communications)

June 14, 2017

(Date of Event which Requires Filing of
this Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include
a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies
are to be sent.

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act
of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other
provisions of the Act (however, see the Notes).

*Includes 62,384 shares of Common Stock issuable upon exercise
of warrants beneficially owned by the Reporting Person.

** The percentage was calculated based on the 16,274,778 shares
of Common Stock outstanding as of June 14, 2017 as reported in the Issuer’s Prospectus pursuant to Rule 424(b)(4) filed
with the Securities and Exchange Commission (the “SEC”) on June 12, 2017.

*Includes 15,668 shares of Common Stock issuable upon exercise
of warrants beneficially owned by the Reporting Person.

** The percentage was calculated based on the 16,274,778 shares
of Common Stock outstanding as of June 14, 2017 as reported in the Issuer’s Prospectus pursuant to Rule 424(b)(4) filed
with the SEC on June 12, 2017.

* The percentage was calculated based on the 16,274,778 shares
of Common Stock outstanding as of June 14, 2017 as reported in the Issuer’s Prospectus pursuant to Rule 424(b)(4) filed
with the SEC on June 12, 2017.

*Includes 157,307 shares of Common Stock issuable upon exercise
of warrants beneficially owned by the Reporting Person.

** The percentage was calculated based on the 16,274,778 shares
of Common Stock outstanding as of June 14, 2017 as reported in the Issuer’s Prospectus pursuant to Rule 424(b)(4) filed
with the SEC on June 12, 2017.

*Includes 235,359 shares of Common Stock issuable upon exercise
of warrants beneficially owned by the Reporting Person.

** The percentage was calculated based on the 16,274,778 shares
of Common Stock outstanding as of June 14, 2017 as reported in the Issuer’s Prospectus pursuant to Rule 424(b)(4) filed
with the SEC on June 12, 2017.

*Includes 235,359 shares of Common Stock issuable upon exercise
of warrants beneficially owned by the Reporting Person.

** The percentage was calculated based on the 16,274,778 shares
of Common Stock outstanding as of June 14, 2017 as reported in the Issuer’s Prospectus pursuant to Rule 424(b)(4) filed
with the SEC on June 12, 2017.

Item 1.    Security and Issuer.

This Amendment No. 1 amends and supplements
the statement on Schedule 13D originally filed by the Reporting Persons (as defined below) with the SEC on March 3, 2015, and
relates to the common stock, $.01 par value (the “Common Stock”) of EyeGate Pharmaceuticals, Inc. (the “Issuer”),
having its principal executive office at 271 Waverley Oaks Road, Suite 108, Waltham, MA 02452. This Amendment No. 1 is being filed
to update the percentage of Common Stock of the Issuer beneficially owned by the Reporting Persons as a result of dilution due
to equity issuances by the Issuer. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information
previously reported on the Schedule 13D. Unless otherwise indicated, each capitalized term used by not defined herein shall have
the meaning assigned to such term in the Schedule 13D.

Item 2.    Identity and Background.

Item 2 is hereby amended and supplemented as follows:

The persons named in this Item 2(a) are
referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.” The
persons named in Item 2(a)(ii) through Item 2(a)(iv) are referred to individually herein as an “Investment Fund” and
collectively as the “Investment Funds.”

Item 4.    Purpose of Transaction.

Item 4 is hereby amended and supplemented as follows:

The Reporting Persons acquired the shares
reported on this schedule (the “Shares”) for investment purposes. Depending on market conditions, its continuing evaluation
of the business and prospects of the Issuer and other factors, the Reporting Persons may dispose of or acquire additional shares
of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result
in:

Item 5.    Interest in Securities of the Issuer.

Item 5 is hereby amended and supplemented as follows:

Each Reporting Person disclaims beneficial ownership
of the Shares other than those shares which such person owns of record.

The percentage of outstanding Common Stock which may
be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet.
Such percentage was calculated based on the 16,274,778 shares of Common Stock outstanding as of June 14, 2017 as reported in the
Issuer’s Prospectus pursuant to Rule 424(b)(4) filed with the SEC on June 12, 2017.

(i)        sole power to vote or to direct the vote: See
line 7 of the cover sheets.

(ii)       shared power to vote or to direct the vote:
See line 8 of the cover sheets.

(iii)      sole power to dispose or to direct the disposition:
See line 9 of the cover sheets.

(iv)      shared power to dispose or to direct the disposition:
See line 10 of the cover sheets.

As a result primarily of offerings of Common Stock by the Issuer
in August 2015, June 2016 and June 2017, the Reporting Persons’ ownership in the Issuer as reported on the original Schedule
13D has been diluted.

Item 7.    Material to be Filed as Exhibits.

Exhibit 1 — Agreement regarding filing of joint Schedule
13D.

SIGNATURES

After reasonable inquiry and to the best
of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete
and correct.